InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Medindia

Medications and their Potential to Cause Increase 'Pyoderma'

This page lists all known medications that could potentially lead to 'Pyoderma' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...
Healio

Pain scores may indicate treatment response in patients with pyoderma gangrenosum

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...
Healio

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
Nature

Therapy Insight: pyoderma gangrenosum—old disease, new management

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...
Nature

Infliximab for the treatment of pyoderma gangrenosum

Pyoderma gangrenosum is a chronic ulcerating skin disorder of unknown cause that develops in approximately 2% of patients with inflammatory bowel disease (IBD). Several case reports have indicated ...
Medindia

Medications and their Potential to Cause Increase 'Pyoderma gangrenosum'

This page lists all known medications that could potentially lead to 'Pyoderma gangrenosum' as a side effect. It's important to note that mild side effects are quite common with medications. The ...